Historical Financial Review
T he
is prepared once per year and is available on line at
It is intended to supplement the Annual
Report and other SEC filings and be used primarily by financial analysts to assist in a detailed financial analysis. While this document does include abbreviated financial statements,
We appreciate your comments and suggestions on ways to improve this document and will attempt to incorporate them into future editions .
Introduction
Five –Year Selected Financial Data
Description of Major Business Franchises
Balance Sheets, Statements of Earnings, Statements of Cash Flows
Segments of Business Information
Geographical Areas
Sales Growth Rates
Quarterly Sales and Earnings Information
Historical Sales and Net Earnings
Stock Split and Share Repurchase Information
Historical Common Stock Information
Reconciliation of Non-GAAP Measures
Corporate and Shareholder/Investor Information
11
12-15
16
17
18-19
20
21
1
2
3-4
5-7
8-9
10
1

Johnson & Johnson and Subsidiaries:
Sales to customers
Earnings before provision for taxes on income
Net earnings attributable to J&J
(2)
Basic net earnings per share
Diluted net earnings per share
Before tax margin
Net profit margin
(2)
Effective tax rate
Return on average shareholders' equity
Return on total assets
Cash and Current Marketable Securities
Debt
Equity
Total capital
Net cash/(debt)
Total debt/total capital
Dividends paid per share
Shareholders' equity per share
Market price per share (year end close)
Average shares outstanding (mm) - basic
- diluted
Cash dividends
Total assets*
Research & development expense
Capital expenditures
Number of employees (thousands)
2015
(1)
$ 70,074
19,196
15,409
5.56
5.48
2014
(1)
74,331
20,563
16,323
5.80
5.70
27.4
22.0
19.7
21.9
11.6
% 27.7
22.0
20.6
22.7
12.5
$ 38,376
19,861
71,150
91,011
$ 18,515
33,089
18,760
69,752
88,512
$ 14,329
21.8
% 21.2
$ 2.950
25.82
102.72
2,771.8
2,812.9
$ 8,173
$ 133,411
9,046
3,463
127.1
105.06
2,815.2
2,863.9
2.760
25.06
7,768
130,358
8,494
3,714
126.5
2013
(1)
(Dollars in Millions Except Per Share Figures)
2012
(1)
2011
(1)
71,312
15,471
13,831
4.92
4.81
67,224
13,775
10,853
3.94
3.86
65,030
12,361
9,672
3.54
3.49
21.7
19.4
10.6
19.9
10.5
29,206
18,180
74,053
92,233
11,026
19.7
2.590
26.25
92.35
2,809.2
2,877.0
7,286
131,754
8,183
3,595
128.1
20.5
16.1
23.7
17.8
8.9
16,165
64,826
80,991
4,924
21,089
20.0
2.400
23.33
69.48
2,753.3
2,812.6
6,614
121,347
7,665
2,934
127.6
19.0
14.9
21.8
17.0
8.5
32,261
19,627
57,080
76,707
12,634
25.6
2,736.0
2,775.3
2.250
20.95
65.58
6,156
113,644
7,548
2,893
117.9
(1) For Adjusted earnings (before and after tax) and adjusted earnings per share, see Reconciliation of Non-GAAP Measures on Page 20.
(2) After noncontrolling interests
* Prior year amounts have been reclassified to conform to current year presentation
2

Description of Major Business Franchises
Consumer Segment
The Consumer segment includes a broad range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Baby Care includes the JOHNSON’S® line of products. Oral
Care includes the LISTERINE® product line. Major brands in
Skin Care include the AVEENO®; CLEAN & CLEAR®; DABAO™;
JOHNSON’S® Adult; LE PETITE MARSEILLAIS®; LUBRIDERM®;
NEUTROGENA®; and RoC® product lines. Over-the-counter medicines include the broad family of TYLENOL® acetaminophen products; SUDAFED® cold, flu and allergy products; BENADRYL® and ZYRTEC® allergy products;
MOTRIN® IB ibuprofen products; and the PEPCID® line of heartburn products. Major brands in Women’s Health outside of North America are STAYFREE® and CAREFREE® sanitary pads and o.b.® tampon brands. Wound Care brands include the BAND-AID® Brand Adhesive Bandages and NEOSPORIN®
First Aid product lines. These products are marketed to the general public and sold both to retail outlets and distributors throughout the world.
Worldwide Consumer sales of $13.5 billion for the full-year
2015 represented a decrease of 6.8% versus the prior year, consisting of an operational increase of 2.7% and a negative impact from currency of 9.5%. U.S. sales increased 2.5%; international sales decreased 11.9%, which reflected an operational increase of 2.7% and a negative currency impact of 14.6%. In 2015, divestitures had a negative impact of 1.4% on the worldwide Consumer segment operational growth.
Medical Devices Segment
The Medical Devices segment includes a broad range of products used in the orthopaedic, surgery, cardiovascular, diabetes care and vision care fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. They include orthopaedic products; general surgery, biosurgical, endomechanical and energy products; electrophysiology products to treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; diabetes care products, such as blood glucose monitoring and insulin delivery products; and disposable contact lenses.
The Medical Devices segment sales in 2015 were $25.1 billion, a decrease of 8.7% from 2014, which included an operational decline of 1.4% and a negative currency impact of
7.3%. U.S. sales were $12.1 billion, a decrease of 1.0% as compared to the prior year. International sales were $13.0 billion, a decrease of 14.8% as compared to the prior year, with an operational decrease of 1.7% and a negative currency impact of 13.1%. In 2015, the divestitures of the Ortho-
Clinical Diagnostics and the Cordis Businesses had a negative impact of 3.2% and 0.6%, respectively, on the worldwide operational growth of the Medical Devices segment as compared to 2014.
Pharmaceutical Segment
The Pharmaceutical segment is focused on five therapeutic areas: immunology (e.g., rheumatoid arthritis, inflammatory bowel disease and psoriasis), infectious diseases and vaccines
(e.g., HIV, hepatitis, respiratory infections and tuberculosis), neuroscience (e.g., Alzheimer's disease, mood disorders and schizophrenia), oncology (e.g., prostate cancer, hematologic malignancies and lung cancer), and cardiovascular and metabolic diseases (e.g., thrombosis and diabetes). Products in this segment are distributed directly to retailers, wholesalers, hospitals and health care professionals for prescription use.
Key products in the Pharmaceutical segment include:
REMICADE® (infliximab), a treatment for a number of immune-mediated inflammatory diseases; SIMPONI®
(golimumab), a subcutaneous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis and moderately active to severely active ulcerative colitis; SIMPONI ARIA®
(golimumab), an intravenous treatment for adults with moderate to severe rheumatoid arthritis; STELARA®
(ustekinumab), a treatment for adults with moderate to severe plaque psoriasis and active psoriatic arthritis, and for adolescents with moderate to severe psoriasis; OLYSIO®
/SOVRIAD® (simeprevir), for combination treatment of chronic hepatitis C in adult patients; PREZISTA® (darunavir),
EDURANT® (rilpivirine), and PREZCOBIX® /REZOLSTA®
(darunavir/cobicistat), antiretroviral medicines for the treatment of human immunodeficiency virus (HIV-1) in combination with other antiretroviral products; SIRTURO®
(bedaquiline), a diarylquinoline antimycobacterial drug indicated as part of combination therapy in adults (>18 years) with pulmonary multi-drug resistant tuberculosis (MDR-TB);
CONCERTA® (methylphenidate HCl) extended-release tablets
CII, a treatment for attention deficit hyperactivity disorder;
INVEGA® (paliperidone) extended-release tablets, for the treatment of schizophrenia and schizoaffective disorder;
INVEGA SUSTENNA® /XEPLION® (paliperidone palmitate), for the treatment of schizophrenia and schizoaffective disorder in adults; INVEGA TRINZA® (paliperidone palmitate), for the treatment of schizophrenia in patients after they have been adequately treated with INVEGA SUSTENNA® for at least four months; RISPERDAL CONSTA® (risperidone long-acting injection), for the treatment of schizophrenia and the
3

Pharmaceutical Segment (Cont.) maintenance treatment of Bipolar 1 Disorder in adults;
VELCADE® (bortezomib), a treatment for multiple myeloma and for use in combination with rituximab, cyclophosphamide, doxorubicin and prednisone for the treatment of adult patients with previously untreated mantle cell lymphoma; ZYTIGA® (abiraterone acetate), used in combination with prednisone as a treatment for metastatic castration-resistant prostate cancer; IMBRUVICA® (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, or blood cancers, and
Waldenström's Macroglobulinemia; DARZALEX TM
(daratumumab), for the treatment of double refractory multiple myeloma; YONDELIS® (trabectedin), for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen; PROCRIT® (epoetin alfa, sold outside the U.S. as EPREX®), to stimulate red blood cell production; XARELTO® (rivaroxaban), an oral anticoagulant for the prevention of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in patients undergoing hip or knee replacement surgery, to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, for the treatment and reduction of risk of recurrence of DVT and PE; INVOKANA® (canagliflozin), for the treatment of adults with type 2 diabetes; and INVOKAMET®
/VOKANAMET® (canagliflozin/metformin HCl), a combination therapy of fixed doses of canagliflozin and metformin hydrochloride for the treatment of adults with type 2 diabetes. Many of these medicines were developed in collaboration with strategic partners or are licensed from other companies and maintain active lifecycle development programs.
Worldwide Pharmaceutical sales of $31.4 billion for the fullyear 2015 represented a decrease of 2.7% versus the prior year with an operational increase of 4.2% and a negative impact from currency of 6.9%. U.S. sales increased 5.2%; international sales decreased 12.0%, which reflected an operational increase of 3.0% and a negative currency impact of 15.0%. In 2015, acquisitions, divestitures and Hepatitis C sales had a negative impact of 6.8% on the Pharmaceutical segment worldwide operational sales growth. With 12 new medicines launched since 2011, our Pharmaceutical segment is one of the fastest growing of the top 10 pharmaceutical businesses in the U.S., Europe and Japan, and our medicines are making a dramatic impact.
4

Johnson & Johnson and Subsidiaries:
Cash and cash equivalents
Marketable securities
Accounts receivable trade, less allowance for doubtful accounts
Inventories
Other current assets
Total current assets
2015
$ 13,732
24,644
10,734
8,053
3,047
60,210
Property, plant and equipment, net
Intangible assets, net and Goodwill
Other non-current assets
Total assets
15,905
47,393
9,903
$ 133,411
Loans and notes payable
Accounts payable
Accrued liabilities
Accrued taxes on income
Total current liabilities
Long-term debt
Other long-term liabilities
Total liabilities
Common stock
Accumulated other comprehensive income
Retained earnings
Less: common stock held in treasury, at cost
Total shareholders' equity
Total liabilities and shareholders' equity
$ 7,004
6,668
13,325
750
27,747
12,857
21,657
62,261
3,120
(13,165)
103,879
93,834
22,684
$ 71,150
$ 133,411
2014*
14,523
18,566
10,985
8,184
3,486
55,744
16,126
49,054
9,434
130,358
3,638
7,633
13,314
446
25,031
15,122
20,453
60,606
3,120
(10,722)
97,245
89,643
19,891
69,752
130,358
2013*
20,927
8,279
11,713
7,878
4,003
52,800
16,710
50,745
11,499
131,754
4,852
6,266
13,787
738
25,643
13,328
18,730
57,701
3,120
(2,860)
89,493
89,753
15,700
74,053
131,754
* Prior year amounts have been reclassified to conform to current year presentation
5

Johnson & Johnson and Subsidiaries:
Sales to customers
Cost of products sold
Gross profit
Selling, marketing and administrative expenses
Research and development expense
In-process research and development
Interest income
Interest expense, net of portion capitalized
Other (income) expense, net
Restructuring
Earnings before provision for taxes on income
Provision for taxes on income
Net earnings
Add: Net loss attributable to noncontrolling interests
Net earnings attributable to Johnson & Johnson
Basic net earnings per share attributable to J&J
Diluted net earnings per share attributable to J&J
2015
(1)
$ 70,074
2014
(1)
$ 74,331
2013
(1)
$ 71,312
2012
(1)
$ 67,224
2011
(1)
$ 65,030
21,536
48,538
22,746
51,585
22,342
48,970
21,658
45,566
20,360
44,670
21,203
9,046
224
(128)
552
(2,064)
509
21,954
8,494
178
(67)
533
(70)
-
21,830
8,183
580
(74)
482
2,498
-
20,869
7,665
1,163
(64)
532
1,626
-
20,969
7,548
-
(91)
571
2,743
569
19,196
3,787
20,563
4,240
15,471
1,640
13,775
3,261
12,361
2,689
15,409
-
15,409
16,323
-
16,323
13,831
-
13,831
10,514
339
10,853
9,672
-
9,672
$ 5.56
$ 5.48
$ 5.80
$ 5.70
$ 4.92
$ 4.81
$ 3.94
$ 3.86
$ 3.54
$ 3.49
Sales to customers
Cost of products sold
Gross profit
Selling, marketing & administrative expense
Research and development expense
Earnings before provision for taxes on income
Provision for taxes on income
Net earnings attributable to Johnson & Johnson
100.0%
30.7
69.3
30.3
12.9
27.4
5.4
22.0
100.0%
30.6
69.4
29.5
11.4
27.7
5.7
22.0
100.0%
31.3
68.7
30.6
11.5
21.7
2.3
19.4
100.0%
32.2
67.8
31.0
11.4
20.5
4.9
16.1
(1) For adjusted earnings (before and after tax) and adjusted earnings per share, see Reconciliation of Non-GAAP Measures on Page 20.
100.0%
31.3
68.7
32.3
11.6
19.0
4.1
14.9
6

Johnson & Johnson and Subsidiaries:
Net earnings
Adjustments to reconcile net earnings to cash flows:
Depreciation and amortization of property and intangibles
Stock Based Compensation
Venezuela adjustments
Asset write-downs
Net gain on sale of assets/businesses
Net gain on equity investment transactions
Deferred tax provision
Accounts receivable allowances
Changes in assets and liabilities, net of effects from acquisitions:
Increase in accounts receivable
Increase in inventories
(Decrease)/Increase in accounts payable and accrued liabilities
Decrease/(Increase) in other current and non-current assets
Increase/(Decrease) in other current and non-current liabilities
Net cash flows from operating activities
Additions to property, plant and equipment
Proceeds from the disposal of assets / businesses, net
Acquisitions, net of cash acquired
Purchases of investments
Sales of investments
Other
Net cash used by investing activities
Dividends to shareholders
Repurchase of common stock
Proceeds from short-term debt
Retirement of short-term debt
Proceeds from long-term debt
Retirement of long-term debt
Proceeds from the exercise of stock options/excess tax benefits
Other
Net cash used by financing activities
Effect of exchange rate changes on cash and cash equivalents
(Decrease)/Increase in cash and cash equivalents
Cash and cash equivalents, beginning of year
Cash and cash equivalents, end of year
Cash paid during the year for:
Interest
Interest, net of amount capitalized
Income taxes
Treasury stock issued for employee compensation and stock option plans,
net of cash proceeds
Conversion of debt
Fair value of assets acquired
Fair value of liabilities assumed and noncontrolling interests
Net cash paid for acquisitions
2015
$ 15,409
3,746
874
122
624
(2,583)
-
(270)
18
(433)
(449)
(3)
65
2,159
19,279
(3,463)
3,464
(954)
(40,828)
34,149
(103)
(7,735)
(8,173)
(5,290)
2,416
(1,044)
75
(68)
1,295
(57)
(10,846)
$
(1,489)
(791)
14,523
13,732
2014
16,323
3,895
792
87
410
(2,383)
-
441
(28)
(247)
(1,120)
955
442
(1,096)
18,471
(3,714)
4,631
(2,129)
(34,913)
24,119
(299)
(12,305)
(7,768)
(7,124)
1,863
(1,267)
2,098
(1,844)
1,782
-
(12,260)
(310)
(6,404)
20,927
14,523
2013
13,831
4,104
728
108
739
(113)
(417)
(607)
(131)
(632)
(622)
1,821
(1,693)
298
17,414
(3,595)
458
(835)
(18,923)
18,058
(266)
(5,103)
(7,286)
(3,538)
1,411
(1,397)
3,607
(1,593)
2,649
56
(6,091)
(204)
6,016
14,911
20,927
$ 617
515
2,865
603
488
3,536
596
491
3,155
$ 1,196
16
$ 1,174
(220)
$ 954
1,170
17
2,167
(38)
2,129
743
22
1,028
(193)
835
7

Johnson & Johnson and Subsidiaries:
Consumer
United States
International
Total
Pharmaceutical
United States
International
Total
Medical Devices
United States
International
Total
Worldwide
United States
International
Total
2015
(1)
18,333
13,097
31,430
2014
(2)
2013
(3)
17,432
14,881
32,313
13,948
14,177
28,125
2012
(4)
$ 5,222
8,285
13,507
5,096
9,400
14,496
5,162
9,535
14,697
5,046
9,401
14,447
12,421
12,930
25,351
2011
9,732
14,883
(5)
5,151
12,386
11,982
24,368
12,132
13,005
25,137
12,254
15,268
27,522
12,800
15,690
28,490
12,363
15,063
27,426
11,371
14,408
25,779
35,687
34,387
$ 70,074
34,782
39,549
74,331
31,910
39,402
71,312
29,830
37,394
67,224
28,908
36,122
65,030
Consumer
Pharmaceutical
Medical Devices
Segments Total
Less: Expenses not allocated to segments
(6)
Worldwide Total
Consumer
Pharmaceutical
Medical Devices
Segments Total
Worldwide Total
$
11,734
20,347
$
1,787
6,826
1,151
19,196
13.2%
37.3%
27.2%
29.0%
27.4%
1,941
11,696
7,953
21,590
1,027
20,563
13.4
36.2
28.9
29.0
27.7
1,973
9,178
5,261
16,412
941
15,471
13.4
32.6
18.5
23.0
21.7
1,693
6,075
7,187
14,955
1,180
13,775
11.7
24.0
26.2
22.2
20.5
2,096
6,406
5,263
13,765
1,404
12,361
14.1
26.3
20.4
21.2
19.0
Consumer
Pharmaceutical
Medical Devices
Segments Total
General corporate
(7)
Worldwide Total
$
$
20,772
26,144
40,979
87,895
45,516
133,411
21,813
25,803
41,445
89,061
41,297
130,358
23,711
23,783
44,585
92,079
39,675
131,754
24,131
23,219
42,926
90,276
31,071
121,347
24,210
23,747
23,609
71,566
42,078
113,644
(1) 2015 income before tax includes a restructuring charge of $590 million, an intangible asset write-down of $346 million related to Acclarent, Synthes integration costs of
$196 million and $148 million expense for the cost associated with the DePuy ASR
TM
Hip program in the Medical Devices segment. Includes $224 million of in-process research and development expense, comprised of $214 million and $10 million in the Pharmaceutical and Medical Devices segments, respectively. Includes net litigation expense of $141 million comprised of $136 million in the Pharmaceutical segment and $5 million in the Medical Devices segment, which included the gain from the litigation settlement agreement with Guidant for $600 million . The Medical Devices Segment includes a gain of $1.3 billion from the divestiture of the Cordis business. The
Pharmaceutical segment includes a gain of $981 million from the U.S. divestiture of NUCYNTA
®
and a positive adjustment of $0.5 billion to previous reserve estimates, including Managed Medicaid rebates. The Consumer segment includes a gain of $229 million from the divestiture of SPLENDA
®
brand.
(2) 2014 income before tax includes net litigation expense of $1,253 million comprised of $907 million, $259 million and $87 million in the Medical Devices, Pharmaceutical and Consumer segments, respectively. Includes $178 million of in-process research and development expense, comprised of $147 million and $31 million in the
Pharmaceutical and Medical Devices segments, respectively. The Medical Devices segment includes a net gain of $1,899 million from the divestiture of the Ortho-Clinical
Diagnostics business, Synthes integration costs of $754 million and $126 million expense for the cost associated with the DePuy ASR
TM
Hip program. Includes an additional year of the Branded Prescription Drug Fee of $220 million in the Pharmaceutical segment.
(3) 2013 income before tax includes $2,276 million of net litigation expense comprised of $1,975 million and $301 million in the Medical Devices and Pharmaceutical segments, respectively. Includes $683 million of Synthes integration/transaction costs in the Medical Devices segment. Includes $580 million of in-process research and development expense, comprised of $514 million and $66 million in the Pharmaceutical and Medical Devices segments, respectively. The Medical Devices segment also includes $251 million expense for the cost associated with the DePuy ASR
TM
Hip program. Includes $98 million of income related to other adjustments comprised of $55 million and $43 million in the Consumer and Pharmaceutical segments, respectively.
(4) 2012 income before tax includes $1,218 million of net litigation expense comprised of $658 million and $560 million in the Pharmaceutical and Medical Devices segments, respectively. Includes $1,163 million of in-process research and development expense, comprised of $1,111 million and $52 million in the Pharmaceutical and Medical
Devices segments, respectively. Includes $795 million of Synthes integration/transaction costs in the Medical Devices segment. Includes $909 million of asset write-downs and other adjustments, comprised of $499 million, $264 million and $146 million in the Pharmaceutical, Consumer and Medical Devices segments, respectively. The Medical
Devices segment also includes $110 million expense for the cost associated with the DePuy ASR™ Hip program.
(5) 2011 income before tax includes $3,310 million of net litigation expense comprised of $1,741 million and $1,569 million in the Pharmaceutical and Medical Devices segments, respectively. Includes $656 million of net restructuring expense, comprised of $676 million expense in the Medical Devices segment and a gain of $20 million in the Pharmaceutical segment. The Medical Devices segment also includes $521 million expense for the cost associated with the DePuy ASR™ Hip program.
(6) Amounts not allocated to segments include interest (income) expense, noncontrolling interests and general corporate (income) expense. Includes expense of $0.2 billion and $0.5 billion of currency related expense related to the acquisition of Synthes, Inc. in 2012 and 2011, respectively.
(7) General corporate includes cash, cash equivalents & marketable securities. Prior year amounts have been reclassified to conform to current year presentation.
8

Johnson & Johnson and Subsidiaries:
Consumer
Pharmaceutical
Medical Devices
Segments Total
General corporate
Worldwide Total
Consumer
Pharmaceutical
Medical Devices
Segments Total
General corporate
Worldwide Total
2015
$ 544
1,063
1,631
3,238
225
$ 3,463
2014
581
977
1,807
3,365
349
3,714
2013
533
856
1,724
3,113
482
3,595
2012
468
737
1,230
2,435
499
2,934
2011
670
729
1,095
2,494
399
2,893
$ 559
929
1,945
3,433
313
$ 3,746
577
1,053
1,974
3,604
291
3,895
539
1,075
2,224
3,838
266
4,104
575
1,010
1,857
3,442
224
3,666
631
958
1,331
2,920
238
3,158
Consumer segment
Pharmaceutical segment
Medical Devices segment
Worldwide total
Consumer segment
Pharmaceutical segment
Medical Devices segment
Worldwide total
$ 625
6,821
1,600
$ 9,046
629
6,213
1,652
8,494
590
5,810
1,783
8,183
622
5,362
1,681
7,665
659
5,138
1,751
7,548
4.6%
21.7%
6.4%
12.9%
9.7%
4.3
19.2
6.0
11.4
8.4
4.0
20.7
6.3
11.5
8.1
4.3
21.2
6.1
11.4
8.0
4.4
21.1
6.8
11.6
7.9
9

Johnson & Johnson and Subsidiaries:
United States
Europe
Western Hemisphere excluding U.S.
Asia-Pacific, Africa
Total
2015
$ 35,687
15,995
6,045
12,347
$ 70,074
2014
34,782
18,947
7,160
13,442
74,331
2013
31,910
18,599
7,421
13,382
71,312
2012
29,830
16,945
7,207
13,242
67,224
2011
28,908
17,129
6,418
12,575
65,030
United States
Europe
Western Hemisphere excluding U.S.
Asia-Pacific, Africa
Segments total
General corporate
Other non long-lived assets*
Worldwide total
$ 36,609
20,167
62,150
$
2,881
2,493
1,148
70,113
133,411
36,835
21,559
3,210
2,438
64,042
1,138
65,178
130,358
* Prior year amounts have been reclassified to conform to current year presentation
35,880
24,868
3,281
2,434
66,463
992
64,299
131,754
35,115
25,261
3,636
2,362
66,374
899
54,074
121,347
23,529
19,056
3,517
2,163
48,265
750
64,629
113,644
10

Johnson & Johnson and Subsidiaries:
2015
United States
Operations
International
Operations
Currency
Worldwide
Operations
Currency
2.6%
2.6%
-13.1%
1.1%
-14.2%
-5.7%
1.8%
-7.5%
2014
9.0%
9.0%
0.4%
3.7%
-3.3%
4.2%
6.1%
-1.9%
Compound Growth Rates
2010-2015 (5 Yr.)
2005-2015 (10 Yr.)
United States
3.9%
2.3%
International
1.4%
4.5%
Worldwide
2.6%
3.3%
2013
7.0%
7.0%
5.4%
8.2%
-2.8%
6.1%
7.7%
-1.6%
2012
3.2%
3.2%
3.5%
8.4%
-4.9%
3.4%
6.1%
-2.7%
2011
-1.8%
-1.8%
12.4%
7.0%
5.4%
5.6%
2.8%
2.8%
11

Johnson & Johnson and Subsidiaries:
Year U.S.
Consumer
Int'l WW
1Q 2011
2Q 2011
3Q 2011
4Q 2011
2011
$ 1,345
1,339
1,219
1,248
5,151
2,337
2,454
2,521
2,420
9,732
3,682
3,793
3,740
3,668
14,883
1Q 2012
2Q 2012
3Q 2012
4Q 2012
2012
1,316
1,313
1,214
1,203
5,046
2,279
2,306
2,367
2,449
9,401
3,595
3,619
3,581
3,652
14,447
1Q 2013
2Q 2013
3Q 2013
4Q 2013
2013
1,348
1,326
1,225
1,263
5,162
2,327
2,332
2,386
2,490
9,535
3,675
3,658
3,611
3,753
14,697
1Q 2014
2Q 2014
3Q 2014
4Q 2014
2014
1,309
1,320
1,173
1,294
5,096
2,248
2,424
2,416
2,312
9,400
3,557
3,744
3,589
3,606
14,496
1Q 2015
2Q 2015
3Q 2015
4Q 2015
2015
1,359
1,355
1,277
1,231
5,222
2,031
2,128
2,037
2,089
8,285
3,390
3,483
3,314
3,320
13,507
(Dollars in Millions)
U.S.
Pharmaceutical
Int'l WW
$ 3,391
3,239
2,869
2,887
12,386
2,668
2,994
3,113
3,207
11,982
6,059
6,233
5,982
6,094
24,368
3,026
3,094
3,288
3,013
12,421
3,107
3,197
3,114
3,512
12,930
6,133
6,291
6,402
6,525
25,351
3,471
3,377
3,549
3,551
13,948
3,297
3,648
3,487
3,745
14,177
6,768
7,025
7,036
7,296
28,125
3,740
4,613
4,723
4,356
17,432
3,758
3,896
3,584
3,643
14,881
7,498
8,509
8,307
7,999
32,313
4,371
4,543
4,509
4,910
18,333
3,355
3,403
3,185
3,154
13,097
7,726
7,946
7,694
8,064
31,430
12

Johnson & Johnson and Subsidiaries:
Year U.S.
Medical Devices
Int'l WW
1Q 2011
2Q 2011
3Q 2011
4Q 2011
2011
$ 2,872
2,869
2,780
2,850
11,371
3,560
3,702
3,503
3,643
14,408
6,432
6,571
6,283
6,493
25,779
1Q 2012
2Q 2012
3Q 2012
4Q 2012
2012
2,877
2,953
3,289
3,244
12,363
3,534
3,612
3,780
4,137
15,063
6,411
6,565
7,069
7,381
27,426
1Q 2013
2Q 2013
3Q 2013
4Q 2013
2013
3,206
3,243
3,151
3,200
12,800
3,856
3,951
3,777
4,106
15,690
7,062
7,194
6,928
7,306
28,490
1Q 2014
2Q 2014
3Q 2014
4Q 2014
2014
3,155
3,199
2,946
2,954
12,254
3,905
4,043
3,625
3,695
15,268
7,060
7,242
6,571
6,649
27,522
1Q 2015
2Q 2015
3Q 2015
4Q 2015
2015
2,962
3,013
3,005
3,152
12,132
3,296
3,345
3,089
3,275
13,005
6,258
6,358
6,094
6,427
25,137
(Dollars in Millions)
U.S.
Total
Int'l WW
$ 7,608
7,447
6,868
6,985
28,908
8,565
9,150
9,137
9,270
36,122
16,173
16,597
16,005
16,255
65,030
7,219
7,360
7,791
7,460
29,830
8,920
9,115
9,261
10,098
37,394
16,139
16,475
17,052
17,558
67,224
8,025
7,946
7,925
8,014
31,910
9,480
9,931
9,650
10,341
39,402
17,505
17,877
17,575
18,355
71,312
8,204
9,132
8,842
8,604
34,782
9,911
10,363
9,625
9,650
39,549
18,115
19,495
18,467
18,254
74,331
8,692
8,911
8,791
9,293
35,687
8,682
8,876
8,311
8,518
34,387
17,374
17,787
17,102
17,811
70,074
13

Johnson & Johnson and Subsidiaries:
(1)
(Dollars in Millions except per share figures)
Year Sales
Cost of
Products Sold SM&A R&D
In-process
Research and
Development
Net Interest
Exp. (Inc.)
Other Exp.
(Inc.) Restructuring
1Q 2015
2Q 2015
3Q 2015
4Q 2015
2015
$
$
17,374
17,787
17,102
17,811
70,074
$ 5,282
5,357
$
5,224
5,673
21,536
$ 4,847
5,384
$
5,081
5,891
21,203
$
$
1,899
2,129
2,154
2,864
9,046
$ -
-
10
214
$ 224
$ 119
107
91
107
$ 424
$ (348)
(931)
420
(1,205)
$ (2,064)
$
-
509
$ 509
-
-
Year Sales
1Q 2015 100.0%
2Q 2015 100.0%
3Q 2015 100.0%
4Q 2015 100.0%
2015 100.0%
Cost of
Products Sold Gross Margin
30.4%
30.1%
30.5%
31.8%
30.7%
69.6%
69.9%
69.5%
68.2%
69.3%
SM&A
27.9%
30.3%
29.7%
33.1%
30.3%
R&D
10.9%
12.0%
12.6%
16.1%
12.9%
In-process
Research and
Development
Net Interest
Exp. (Inc.) Restructuring
-
-
0.1%
1.2%
0.3%
0.7%
0.6%
0.5%
0.6%
0.6%
-
-
-
2.9%
0.7%
(1) Net Earnings are GAAP and therefore, do not exclude special items.
Refer to Page 20, Reconciliation of Non-GAAP Measures, for an analysis of 2011-2015 Full Year Adjusted Earnings
14

Johnson & Johnson and Subsidiaries:
(1)
(Dollars in Millions except per share figures)
Year
Total Cost &
Expense
Earnings
Before Taxes
Provision for
Taxes on
Income Net Earnings
Basic
Earnings per
Share
Basic
Average
Shares
Diluted
Earnings per
Share
Diluted
Average
Shares
1Q 2015
2Q 2015
3Q 2015
4Q 2015
2015
$
$
11,799
12,046
12,980
14,053
50,878
$ 5,575
5,741
$
4,122
3,758
19,196
$ 1,255
1,225
$
764
543
3,787
$ 4,320
4,516
$
3,358
3,215
15,409
$
$
1.55
1.63
1.21
1.16
5.56
2,782.6
2,772.3
2,768.4
2,763.2
2,771.8
$
$
1.53
1.61
1.20
1.15
5.48
2,826.0
2,812.0
2,807.2
2,803.3
2,812.9
Year
1Q 2015
2Q 2015
3Q 2015
4Q 2015
2015
Other Exp.
(Inc.)
Total Cost &
Expense
Earnings
Before Taxes
Provision for
Taxes on
Income
Income Taxes
(Eff. Rate) Net Earnings
-2.0%
-5.3%
2.5%
-6.8%
-2.9%
67.9%
67.7%
75.9%
78.9%
72.6%
32.1%
32.3%
24.1%
21.1%
27.4%
7.2%
6.9%
4.5%
3.0%
5.4%
22.5%
21.3%
18.5%
14.4%
19.7%
24.9%
25.4%
19.6%
18.1%
22.0%
(1) Net Earnings are GAAP and therefore, do not exclude special items.
Refer to Page 20, Reconciliation of Non-GAAP Measures, for an analysis of 2011-2015 Full Year Adjusted Earnings
15

Johnson & Johnson and Subsidiaries:
(2)
(1)
Year
Net Trade
Sales
$ 0.1
0.2
0.3
0.4
0.4
0.5
0.5
0.6
0.6
0.7
0.7
0.9
1.1
1.3
1.4
1.6
1.8
2.0
2.4
2.7
3.0
2.9
3.2
3.9
4.4
4.6
4.8
5.0
5.1
6.2
9.6
13.7
11.2
15.2
12.5
13.7
15.5
16.0
16.2
16.5
16.8
18.4
19.9
18.7
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
Net
Earnings
0.50
1.30
1.90
1.80
1.80
2.10
2.00
1.50
0.80
1.60
1.20
0.67
0.54
1.05
0.75
0.63
0.74
1.11
1.22
1.37
0.83
$ 0.19
0.13
0.20
0.23
0.23
0.27
0.28
0.36
0.33
0.53
0.77
0.54
0.63
Year
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
Net Trade
Sales
17.4
15.2
17.1
20.7
24.7
28.9
32.3
33.4
35.1
39.1
56.6
78.2
93.1
93.6
96.0
112.6
152.3
165.6
168.3
195.5
227.6
232.2
236.1
243.5
267.5
293.6
315.6
321.2
368.4
384.4
414.5
447.6
462.4
503.3
576.0
660.6
712.3
801.3
901.9
1,002.0
1,140.5
1,317.7
1,611.8
1,937.2
2,224.7
Net
Earnings
1.3
1.1
0.9
1.0
1.3
2.1
1.7
2.7
3.7
2.4
3.2
2.8
3.1
3.1
3.1
8.3
9.9
12.1
10.0
15.7
12.3
8.8
11.2
12.2
14.0
15.6
16.9
15.1
19.7
20.2
17.7
19.9
21.5
26.8
34.4
40.1
45.9
57.6
69.4
83.7
101.8
120.7
148.4
161.6
183.8
(1) Sales restated for EITF change for 1991-2001 only. Net Earnings restated for FAS 123R Share Based Payment for 1996-2005.
(2) Net Earnings attributable to Johnson & Johnson.
Note: 1887-1989 information not restated and may include estimates.
Note: Net Earnings are reported according to GAAP and therefore do not exclude special items.
Refer to Page 20, Reconciliation of Non-GAAP Measures, for an analysis of 2011-2015 Adjusted Earnings.
(Dollars in Millions)
29,172.0
32,317.0
36,298.0
41,862.0
47,348.0
50,514.0
53,324.0
61,095.0
63,747.0
61,897.0
61,587.0
65,030.0
67,224.0
71,312.0
74,331.0
$ 70,074.0
Net Trade
Sales
(1)
2,522.5
2,914.1
3,497.3
4,211.6
4,837.4
5,399.0
5,760.9
5,972.9
6,124.5
6,421.3
7,003.0
8,011.5
8,999.5
9,829.0
11,365.0
12,210.0
13,600.0
13,877.0
15,454.0
18,537.0
21,387.0
22,522.0
23,811.0
27,357.0
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
Year
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1,786.0
1,961.0
2,416.0
2,942.0
3,070.0
3,024.0
4,133.0
4,764.0
5,405.0
6,277.0
6,848.0
8,180.0
10,060.0
11,053.0
10,576.0
12,949.0
12,266.0
13,334.0
9,672.0
10,853.0
13,831.0
16,323.0
$ 15,409.0
Net Earnings
205.4
247.3
299.1
352.1
400.7
467.6
473.0
489.0
514.5
613.7
330.0
833.0
974.0
1,082.0
1,080.0
1,270.0
977.0
16

Johnson & Johnson and Subsidiaries:
Pay Out Date
May 5, 1947
November 15, 1948
November 15, 1949
March 20, 1951
January 9, 1959
June 19, 1967
May 15, 1970
May 18, 1981
May 10, 1989
June 9, 1992
June 11, 1996
June 12, 2001
Year
1984
1986
1988
1992
1993
2002
2006
2007
2008
2009
2010
2014
(1)
2015
(2)
Total Shares
(Millions)
160.0
160.0
97.8
42.4
49.6
83.6
81.8
55.8
69.1
15.5
17.9
33.7
24.8
Action
100% Stock Dividend
5% Stock Dividend
5% Stock Dividend
5% Stock Dividend
2 1/2 for 1 Split
200% Stock Dividend
3 for 1 Split
3 for 1 Split
2 for 1 Split
2 for 1 Split
2 for 1 Split
2 for 1 Split
Total Value
(Dollars in Millions)
$329
670
500
500
500
5,000
5,000
3,600
4,500
800
1,100
3,500
2,500
(Dollars in Millions)
Avg. Price
Per Share
$2.0550
4.1865
5.1230
11.7975
10.0625
59.7994
61.1247
64.5870
65.1230
51.6129
61.4525
103.8576
100.8065
* Total value may be rounded. In addition, the Company repurchases shares annually for use in employee stock option and employee incentive plans. In 1990, the Company repurchased 12.8 million shares for a total value of $100 million in connection with the establishment of an ESOP. All shares and average price per share have been adjusted for stock split.
(1)
On July 21, 2014, the Company announced that is Board of Directors approved a share repurchase program, authorizing the
Company to purchase up to $5.0 billion of the Company's Common Stock. The repurchase program was completed on April 28,
2015
(2)
On October 13, 2015, the Company announced that its Board of Directors approved a share repurchase program, authorizing the
Company to purchase up to $10.0 billion of the Company's Common Stock.
17

YEAR
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
9/25/44 (open)
1944
1945
1946
1947
1948
1949
1950
$
YEARLY
HIGH
9.27
14.53
14.67
12.60
14.13
23.10
2.68
3.45
4.64
6.59
5.51
7.44
1.86
1.68
2.11
2.46
3.20
3.22
1.25
2.08
2.77
2.76
2.49
2.08
2.01
1.63
0.28
0.40
0.47
0.67
0.75
1.26
0.09
0.14
0.17
0.18
0.26
0.26
0.29
0.08
0.07
0.06
0.07
0.08
0.08
0.02
$
0.03
0.03
0.03
0.03
0.05
0.07
Johnson & Johnson and Subsidiaries:
YEARLY
LOW
6.39
8.17
10.75
8.91
9.00
13.41
1.75
2.20
2.86
3.44
4.35
5.19
1.37
1.35
1.38
1.77
2.03
2.44
0.89
1.18
1.96
2.11
1.52
1.51
1.49
1.30
0.22
0.26
0.32
0.38
0.52
0.70
0.07
0.08
0.11
0.13
0.17
0.14
0.17
0.06
0.05
0.05
0.06
0.06
0.06
0.01
$
0.02
0.02
0.02
0.03
0.03
0.04
YEARLY
AVERAGE
$
YEAR-END
PRICE
YEARLY
DIVIDEND
8.97
14.31
12.63
11.22
13.69
21.38
2.26
3.29
4.10
4.68
5.32
7.42
1.54
1.65
2.08
2.32
3.10
2.55
1.19
2.05
2.72
2.35
1.69
1.87
1.63
1.60
0.26
0.40
0.40
0.64
0.74
1.25
0.08
0.12
0.14
0.17
0.24
0.17
0.24
0.06
0.06
0.06
0.07
0.07
0.07
0.02
0.01
$ 0.00008
0.02
0.00012
0.03
0.02
0.00012
0.00020
0.03
0.05
0.07
0.00067
0.00115
0.00176
0.00102
0.00093
0.00152
0.00152
0.00152
0.00152
0.00167
0.00157
0.00185
0.00231
0.00231
0.00231
0.00255
0.03542
0.04167
0.04646
0.05313
0.06625
0.06750
0.07375
0.08000
0.08625
0.10063
0.12000
0.14000
0.16375
0.19250
0.22250
0.25250
0.28250
0.32000
0.00278
0.00336
0.00382
0.00428
0.00451
0.00590
0.00708
0.00896
0.00932
0.01094
0.01510
0.01771
0.02188
0.02917
7.85
11.19
12.34
10.50
11.54
17.19
2.16
2.78
3.97
5.28
5.06
6.25
1.61
1.52
1.67
2.06
2.55
2.86
1.06
1.74
2.50
2.47
1.97
1.85
1.84
1.46
0.25
0.35
0.41
0.50
0.63
0.99
0.08
0.11
0.16
0.16
0.22
0.22
0.24
0.07
0.06
0.06
0.06
0.07
0.07
0.02
0.02
0.02
0.03
0.03
0.03
0.05
(Price per share/Shares in Millions)
NET SHARES
OUTSTANDING*
2,872.9
2,938.2
2,966.6
2,993.0
3,026.0
3,061.3
2,925.5
2,925.6
2,765.6
2,753.5
2,664.6
2,679.4
2,700.4
2,713.4
2,674.2
2,627.8
2,645.0
2,665.6
2,574.6
2,603.0
2,588.2
2,606.1
2,619.4
2,656.4
2,676.3
2,690.8
2,708.1
2,761.1
2,773.6
2,785.7
2,796.1
2,808.3
2,213.6
2,213.6
2,242.7
2,264.0
2,276.0
2,243.1
2,247.9
2,260.2
2,264.1
2,259.8
2,268.4
2,274.9
2,270.4
2,276.6
2,288.0
2,290.3
2,558.8
2,563.5
2,586.3
2,584.8
2,591.9
P/E
RATIO
14
15
43
17
16
19
21
30
23
17
19
25
14
12
15
15
16
14
28
30
22
16
43
54
59
41
27
32
28
33
34
41
14
22
23
28
31
24
29
18
15
15
17
15
12
10
19
7
6
6
12
12
18

Johnson & Johnson and Subsidiaries:
(Price per share/Shares in Millions)
YEAR
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
1996
1997
1998
1999
2000
2001
2002
2003
YEARLY
HIGH
64.25
64.60
69.41
68.75
72.76
65.41
66.20
68.05
72.74
95.99
109.49
106.50
27.00
33.66
44.88
53.44
52.97
60.97
65.89
59.08
YEARLY
LOW
49.25
59.76
56.70
59.72
52.06
46.25
56.86
57.50
61.71
69.18
86.09
81.79
20.78
24.32
31.69
38.50
33.07
40.25
41.40
48.05
YEARLY
AVERAGE
55.84
64.70
62.21
63.98
64.91
56.88
62.16
63.56
66.95
85.65
100.82
99.76
24.29
29.82
37.46
46.99
44.64
51.88
57.67
52.62
YEAR-END
PRICE
63.42
60.10
66.02
67.38
58.56
64.41
61.85
65.58
69.48
92.35
105.06
102.72
24.88
32.97
41.94
46.63
52.53
59.86
53.11
50.62
YEARLY
DIVIDEND
0.36750
0.42500
0.48500
0.54500
0.62000
0.70000
0.79500
0.92500
1.09500
1.27500
1.45500
1.62000
1.79500
1.93000
2.11000
2.25000
2.40000
2.59000
2.76000
2.95000
* Net shares outstanding = shares issued less treasury stock at Johnson & Johnson year-end close.
Note: All data adjusted for prior stock splits; shares outstanding are actual J&J year-end close; yearly average share price per
Yahoo Finance for J&J 2015 fiscal year; year-end share price per Yahoo Finance at J&J year-end close; P/E ratio based
on fiscal year-end closing price.
NET SHARES
OUTSTANDING*
2,753.4
2,971.6
2,975.3
2,979.6
3,014.6
3,047.2
2,968.3
2,967.9
2,971.0
2,971.0
2,893.2
2,840.2
2,769.2
2,754.3
2,738.1
2,724.4
2,778.5
2,820.6
2,783.2
2,755.2
P/E
RATIO
23
18
18
18
13
15
13
19
18
19
18
19
25
32
41
34
33
34
25
22
19

Johnson & Johnson and Subsidiaries:
Earnings before provision for taxes on income- as reported
Litigation expense, net
Ortho-Clinical Diagnostics divestiture net gain
Additional year of Branded Prescription Drug Fee
DePuy ASR
TM
Hip program
Synthes integration costs
In-process research & development
Intangible asset write-downs
Restructuring
Intangible asset amortization expense
Other
Earnings before provision for taxes on income- as adjusted
Net Earnings
(1)
- as reported
Litigation expense, net
Ortho-Clinical Diagnostics divestiture net gain
Additional year of Branded Prescription Drug Fee
Tax benefit associated with Conor Medsystems
DePuy ASR
TM
Hip program
Synthes integration costs
In-process research & development
Scios Tax Benefit
Intangible asset write-downs
Restructuring
Intangible asset amortization expense
Other
Net Earnings
(1)
- as adjusted
$ 15,409
118
(46)
-
-
130
144
162
-
-
415
1,113
-
$ 17,445
2015
$ 19,196
141
(62)
-
148
196
224
-
590
1,570
-
$ 22,003
2014
20,563
1,253
(1,899)
220
126
754
178
-
-
1,630
-
22,825
16,323
1,225
(1,062)
(2)
220
(398)
111
555
131
-
-
-
1,213
-
$ 18,318
13,831
1,646
-
-
-
240
483
462
(707)
-
-
1,148
(79)
17,024
(Dollars in Millions except per share amounts)
2013
15,471
2,282
-
-
251
683
580
-
-
1,522
(98)
20,691
2012
13,775
1,229
-
-
110
1,028
1,163
939
-
1,175
(30)
19,389
2011
12,361
3,310
-
-
521
491
14
-
656
852
-
18,205
10,853
1,052
-
-
-
97
899
743
-
717
-
838
(16)
15,183
(3)
9,672
2,745
-
-
-
426
477
11
-
-
536
593
-
14,460
Diluted net earnings per share
(1)
Litigation expense, net
- as reported
Ortho-Clinical Diagnostics divestiture net gain
Additional year of Branded Prescription Drug Fee
Tax benefit associated with Conor Medsystems
DePuy ASR
TM
Hip program
Synthes integration costs
In-process research & development
Scios Tax Benefit
Intangible asset write-downs
Restructuring
Intangible asset amortization expense
Other
Diluted net earnings per share
(1)
- as adjusted
$ 5.48
0.04
(0.02)
-
-
0.05
0.05
0.06
-
-
0.15
0.39
-
$ 6.20
5.70
0.43
(0.37)
0.08
(0.14)
0.04
0.19
0.04
-
-
-
0.42
-
6.39
4.81
0.57
-
-
-
0.08
0.17
0.16
(0.25)
-
-
0.40
(0.02)
5.92
3.86
0.37
-
-
-
0.03
0.32
0.27
-
0.26
-
0.30
(0.01)
5.40
3.49
0.99
-
-
-
0.16
0.17
-
-
-
0.19
0.21
-
5.21
(1) Attributable to Johnson & Johnson
(2) Includes adjustment to deferred tax asset related to deductibility by tax jurisdiction
(3) Amount includes in-process research and development charge of $679M related to bapineuzumab IV offset by $339M reported as net loss attributable to noncontrolling interest
The Company believes investors gain additional perspective of underlying business trends and results by providing a measure of earnings before provision for taxes on income, net earnings and diluted net earnings per share that excludes intangible asset amortization expense and special items in order to evaluate ongoing business operations. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.
20

Corporate and Shareholder/Investor Information
Principal Office
One Johnson & Johnson Plaza
New Brunswick, New Jersey 08933
(732) 524-0400
Common Stock
Listed on New York Stock Exchange
Stock Symbol: JNJ
Annual Meeting
The Annual Meeting of Shareholders will take place on Thursday, April 28, 2016, at the
State Theatre, 15 Livingston Avenue, New
Brunswick, New Jersey. The meeting will convene at 10 a.m. All shareholders as of the record date of March 1, 2016 are cordially invited to attend. A formal Notice of Annual
Meeting, Proxy Statement and Proxy have been sent to shareholders.
Transfer Agent and Registrar
Questions regarding stock holdings, certificate replacement/transfer, dividends and address changes should be directed to:
Computershare Trust Company, N.A.
250 Royall St.
Canton, MA 02021
(800) 328-9033 or
(781) 575-2718 (outside the U.S.) www.computershare.com
Dividend Reinvestment Plan
The Plan allows for full or partial dividend reinvestment and additional monthly cash investments up to $50,000 per year in
Johnson & Johnson Common Stock without brokerage commissions or service charges on stock purchases. If you are interested in participating in the Plan and need an authorization form and/or more information, please call Computershare Trust Company,
N.A. at (800) 328-9033 or (781) 575-2718
(outside the U.S.).
Shareholder Relations Contact
Elizabeth Forminard
WW Vice President - Corporate Governance
(732) 524-6232
Investor Relations Department
One Johnson & Johnson Plaza
New Brunswick, New Jersey 08933
1-800-950-5089
Fax: (732) 524-3867
Louise Mehrotra
Vice President, Investor Relations
(732) 524-6492
Jason Valmore
Senior Director, Investor Relations
(732) 524-3709
Lesley Fishman
Senior Director, Investor Relations
(732) 524-3922
Lisa Romanko
Senior Director, Investor Relations
(732) 524-2034
Renee McKenna
Senior Analyst
(732) 524-6492
Reports Available
Copies of the Company's 2015 Annual
Report on Form 10-K, Quarterly Reports on
Form 10-Q and Current Reports on Form
8-K to the Securities and Exchange
Commission, Proxy Statement and the
Annual Report are available online at www.jnj.com
or to shareholders without charge upon written request to the
Secretary at the Company's principal address or by calling (800) 328-9033 or
(781) 575-2718 (outside the U.S.)
Press Releases
Press releases, including earnings reports, are available via web access http://www.jnj.com
Internet Access
Visit the Johnson & Johnson Home
Page on the
Internet: http://www.jnj.com
© Johnson & Johnson 2015
Trademarks and service marks of Johnson & Johnson and its affiliated companies are designated by all capital letters in this publication
21